Could cause temporary or reversible harm; serious harm is unlikely.
Lack of Assurance of Sterility: a recent FDA inspection at the manufacturing firm raised concerns that product sterility may be compromised.
| Distributed by / for | Sandoz Inc., Princeton, NJ 08540 |
| NDC | 66758-016-03 |
| Full product label | Phenylephrine HCI Injection, USP, 10mg/mL, packaged in a) 5 mL Vial, 50 mg/5 mL (NDC 66758-016-03), 25 x 5 mL Vials per carton (NDC 66758-016-04) and b) 10 mL Vials, 100 mg/10 mL (NDC 66758-017-01), Rx only, Manufactured for: Sandoz Inc., Princeton, NJ 08540. |
| Recalling firm | Sandoz Inc |
| Distribution | Nationwide and Puerto Rico |
| Quantity | a) 1,584 cartons; b) 62,170 vials |
| Recall initiated | 2016-08-24 |
| Report date | 2016-09-28 |
| Recall completed | 2017-07-12 |
| Recall number | D-1514-2016 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Princeton NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗